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Autoimmune Progesterone Dermatitis Diagnosed by 
Lymphocyte Transformation Test and Progesterone 
Provocation Test
Autoimmune progesterone dermatitis (APD) is 
rare autoimmune response to endogenous proges-
terone or to earlier exposure to exogenous progester-
one (1). Skin lesions typically occur due to increases 
in progesterone during the luteal phase of the men-
strual cycle (2). 
A-31-year-old mother of two children presented 
to our Department with a 5-year history of pruritic 
and painful erythematosus macules, papules, and 
patches on her neck, pectoral region, and face, which 
appeared 2-3 days before the onset of menses and 
gradually resolved 7-10 days later (Figure 1). The le-
sions first appeared 10 months after her second preg-
nancy and a few months after she had started using 
oral contraceptive pills (OCP) containing gestodene 
combined with ethinyloestradiol. A few months be-
fore presenting to us, the lesions had started spread-
ing on her forearms, elbows, and pretibial areas. 
Since one year prior to our visit she had complained 
of occasional urticaria with angioedema one week 
prior to menses, which resolved after menses. The le-
sions were accompanied by malaise, headache, and 
fatigue. The patient was asymptomatic between the 
outbreaks. She reported that she had been using vari-
ous local corticosteroids, peroral antihistamines, and 
prednisone for the treatment of her skin lesions, but 
this treatment had not improved her symptoms. She 
suffered from mild seasonal rhinoconjunctivitis.
We performed multiple laboratory tests that were 
unremarkable. Histopathological examination of a 
biopsy taken from a lesion on the neck showed epi-
dermal hyperplasia and nonspecific mild dermal in-
flammation. Since progesterone was not available in 
aqueous solution in our country, we did not perform 
an intradermal test, but we performed a lymphocyte 
transformation test (LTT) to medroxyprogesterone 
and estradiol. The patient’s lymphocytes showed 
markedly enhanced proliferation to medroxypro-
gesterone in vitro, while being negative to estradiol. 
We had performed control LTT in 10 healthy controls 
and 10 patients with atopy, and such hyperactivity 
was not observed in any of them. We performed an 
oral provocation test with OCP containing gestodene 
combined with ethinyloestradiol. Two days after 
commencing treatment, the patient developed wide-
spread dermatitis (Figure 2) with nausea, malaise, and 
angioedema. The patient was informed about treat-
ment options and possible side-effects. She started 
Figure 2. Papular and urticarial patches on the arms a few 
days after oral provocation test with oral contraceptive 
pills (OCP) containing gestodene combined with ethi-
nyloestradiol.
Figure 1. Erythematous, indurated patchy skin eruptions 
on the face.
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with OCP with the lowest amount of progesterone, 
containing ethinyloestradiol and dropirenone for 
treatment of APD, but terminated treatment after the 
second cycle due to a worsening of the skin lesions 
and urticaria accompanied with angioedema. At the 
time of writing, our patient continues to have pre-
menstrual flares. 
The typical symptoms of APD are skin lesions 
such as eczema, erythema multiforme, prurigo, sto-
matitis, papulopustular lesions, folliculitis, urticaria, 
angioedema, and rarely anaphylaxis (2) that develop 
3-10 days before and subside 1-2 days after menses, 
with recurrent cyclic aggravation (1,3,4). Frequently, 
patients have a history of exogenous progesterone 
intake (1,5,6), as in our patient, which could have re-
sulted in antibody formation. The diagnosis of APD 
is established by an appropriate clinical history (pre-
menstrual flare of skin lesions), a progesterone intra-
dermal test, an intramuscular (7), oral (8), or intravagi-
nal (1, 6) progesterone challenge test, and circulating 
antibodies to progesterone. Progesterone testing has 
not been standardized. Most of the sex hormones 
are not suitable for testing since they contain an oily 
component that can produce an irritant test reaction. 
Gestodene, which was used for the oral provocation 
test in our patient, is a potent progesterone (9). The 
LTT shows reactions to circulating lymphocytes and 
reflects immune reactions within the body. The goal 
of treatment is suppression of ovulation. Currently, 
the first-line choice of therapy is a combination oral 
contraceptive (3). We believe that OCP have a limited 
effect because all of them contain a progesterone 
component. If this treatment is ineffective, patients 
have been treated with danazol, gonadotropin releas-
ing hormone analogs (3,4,6), conjugated estrogens 
(7), tamoxifen, oophorectomy (8), and progestogen 
desensitization (10) with varying success.
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